Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 693.35

-0.2%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (2410)	5/8/2018 1:25:14 PM
From: Miljenko Zuanic	of 3559

RE:2810 at ASCO Some optimism can be expected from 2L BCC trial (options for "to be" pivotal), possibility for some additional small market share in PD-L1 positive space. Still, all this can not substitute/ease "fear" from Eylea market share loss and revenue growth slowdown. Dupi continue to be key drug for now, expect further price erosion until its future is resolved, IF at all. Regardless, REGN continue to invest in manufacturing facility (US and Ireland), expecting growth in drug demand. Who is right, who is wrong...time will tell?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next